The estimated Net Worth of Paula Soteropoulos is at least $1.67 million dollars as of 13 June 2024. Ms. Soteropoulos owns over 2,220 units of uniQure N.V stock worth over $110,510 and over the last 8 years she sold QURE stock worth over $1,330,943. In addition, she makes $230,005 as Non-Executive Independent Director at uniQure N.V.
Sign up
Ms. Soteropoulos QURE stock SEC Form 4 insiders trading
Paula has made over 18 trades of the uniQure N.V stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 2,220 units of QURE stock worth $11,411 on 13 June 2024.
The largest trade she's ever made was exercising 2,061,861 units of uniQure N.V stock on 26 September 2019 worth over $14,536,120. On average, Paula trades about 80,023 units every 86 days since 2017. As of 13 June 2024 she still owns at least 20,203 units of uniQure N.V stock.
You can see the complete history of Ms. Soteropoulos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paula Soteropoulos biography
Paula Soteropoulos serves as Non-Executive Independent Director of the Company. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. Since March 2020, she serves as Strategic Advisor to 5AM Ventures and is Executive Chairman of a 5AM Venture NewCo. From January 2015 through September 2019, she served as President and Chief Executive Officer of Akcea Therapeutics (NASDAQ: AKCA). From July 2013 to December 2014, she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
What is the salary of Paula Soteropoulos?
As the Non-Executive Independent Director of uniQure N.V, the total compensation of Paula Soteropoulos at uniQure N.V is $230,005. There are 13 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
How old is Paula Soteropoulos?
Paula Soteropoulos is 52, she's been the Non-Executive Independent Director of uniQure N.V since . There are 10 older and 4 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
What's Paula Soteropoulos's mailing address?
Paula's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Insiders trading at uniQure N.V
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos et William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
What does uniQure N.V do?
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
What does uniQure N.V's logo look like?
Complete history of Ms. Soteropoulos stock trades at uniQure N.V et Akcea Therapeutics Inc
uniQure N.V executives and stock owners
uniQure N.V executives and other stock owners filed with the SEC include:
-
Matthew Kapusta,
Chief Executive Officer, Chief Financial Officer, Executive Director -
Robert Gut,
Executive Director -
Alexander Kuta,
Executive Vice President, Operations -
Maria Cantor,
Senior Vice President, Investor Relations and Communications -
Matthew Craig Kapusta,
CEO & Exec. Director -
Dr. Alexander E. Kuta Ph.D.,
Exec. VP of Quality & Regulatory -
Dr. Ricardo Dolmetsch Ph.D.,
Pres of R&D -
Christian Klemt,
CFO, Principal Financial Officer & GM of Amsterdam Site -
David Meek,
Non-Executive Independent Director -
Philip Astley-Sparke,
Independent Non-Executive Chairman of the Board -
Jack Kaye,
Non-Executive Independent Director -
Jeremy Springhorn,
Non-Executive Independent Director -
Madhavan Balachandran,
Non-Executive Independent Director -
Paula Soteropoulos,
Non-Executive Independent Director -
Leonard Post,
Director -
Ricardo Dolmetsch,
President, Research and Development -
Erin Boyer,
Chief People & Culture Office -
Richard Porter Ph.D.,
SVP of R&D and GM of Corlieve -
Dr. Tamara Tugal Ph.D., MBA,
Bus. Devel. Director -
Maria E. Cantor,
Chief Communications Officer -
David Cerveny,
Chief Legal Officer, Gen. Counsel & Sec. -
Pierre Caloz,
Chief Operating Officer -
Prof. Hugo Katus,
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -
Rachelle Suzanne Jacques,
Director -
Christian Meyer,
Chief Medical Officer -
Harald Petry,
Chief Scientific Officer -
Maiken Keson Brookes,
General Counsel -
Jonathan Garen,
Chief Business Officer -
David Schaffer,
Director -
Paul E Firuta,
Chief Commercial Officer -
William Lewis,
Director -
Steven Zelenkofske,
Chief Medical Officer -
Deventer Sander Van,
EVP, Research & Product Dev. -
Scott T. Mc Millan,
Chief Operating Officer -
Pierre Caloz,
Chief Operating Officer -
Christian Klemt,
Chief Financial Officer -
Jeannette Potts,
Chief Legal Officer -
Walid Abi Saab,
Chief Medical Officer